“We are rapidly approaching a significant Vera milestone with the upcoming primary endpoint results from the pivotal atacicept ORIGIN 3 trial, and if successful, we expect this to enable a BLA submission to the FDA in the second half of this year, which may allow approval and commercial launch in 2026. If approved, we believe that atacicept has the potential to advance the standard of care in IgA nephropathy,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics (VERA). “The Vera team is well-positioned to build on the success of the lead atacicept development program in IgAN, with the expansion into additional potential indications in other autoimmune kidney diseases and beyond.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics assumed with a Buy at H.C. Wainwright
- Positive Outlook for Vera Therapeutics: Buy Rating on Atacicept’s Potential in IgA Nephropathy
- Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept
- 3 Best Stocks to Buy Now, 3/27/2025, According to Top Analysts
- Vera Therapeutics, Inc. (VERA) Q4 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue